18 Mar 2026 | 3 Mins Read
USFDA Action Affects Aurobindo Pharma Shares
Flipitmoney
Aurobindo Pharma's Eugia Pharma Unit II received "Official Action Indicated" (OAI) classification from the USFDA after a November inspection with nine observations. The company sees no material impact but faces ongoing regulatory scrutiny with Unit III also under OAI status and a May 2024 warning letter. Shares rose 0.80% to ₹1,289.80 on Tuesday.